TY - JOUR
T1 - ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement
AU - Faroux, Laurent
AU - Lhermusier, Thibault
AU - Vincent, Flavien
AU - Nombela-Franco, Luis
AU - Tchétché, Didier
AU - Barbanti, Marco
AU - Abdel-Wahab, Mohamed
AU - Windecker, Stephan
AU - Auffret, Vincent
AU - Campanha-Borges, Diego Carter
AU - Fischer, Quentin
AU - Muñoz-Garcia, Erika
AU - Trillo-Nouche, Ramiro
AU - Jorgensen, Troels
AU - Serra, Vicens
AU - Toggweiler, Stefan
AU - Tarantini, Giuseppe
AU - Saia, Francesco
AU - Durand, Eric
AU - Donaint, Pierre
AU - Gutierrez-Ibanes, Enrique
AU - Wijeysundera, Harindra C.
AU - Veiga, Gabriela
AU - Patti, Giuseppe
AU - D'Ascenzo, Fabrizio
AU - Moreno, Raul
AU - Hengstenberg, Christian
AU - Chamandi, Chekrallah
AU - Asmarats, Lluis
AU - Hernandez-Antolin, Rosana
AU - Gomez-Hospital, Joan Antoni
AU - Cordoba-Soriano, Juan Gabriel
AU - Landes, Uri
AU - Jimenez-Diaz, Victor Alfonso
AU - Cruz-Gonzalez, Ignacio
AU - Nejjari, Mohammed
AU - Roubille, François
AU - Van Belle, Éric
AU - Armijo, German
AU - Siddiqui, Saifullah
AU - Costa, Giuliano
AU - Elsaify, Sameh
AU - Pilgrim, Thomas
AU - le Breton, Hervé
AU - Urena, Marina
AU - Muñoz-Garcia, Antonio Jesus
AU - Sondergaard, Lars
AU - Bach-Oller, Montserrat
AU - Fraccaro, Chiara
AU - Eltchaninoff, Hélène
AU - Metz, Damien
AU - Tamargo, Maria
AU - Fradejas-Sastre, Victor
AU - Rognoni, Andrea
AU - Bruno, Francesco
AU - Goliasch, Georg
AU - Santaló-Corcoy, Marcelo
AU - Jimenez-Mazuecos, Jesus
AU - Webb, John G.
AU - Muntané-Carol, Guillem
AU - Paradis, Jean Michal
AU - Mangieri, Antonio
AU - Ribeiro, Henrique Barbosa
AU - Campelo-Parada, Francisco
AU - Rodés-Cabau, Josep
N1 - Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/5/4
Y1 - 2021/5/4
N2 - Background: Among patients with acute coronary syndrome following transcatheter aortic valve replacement (TAVR), those presenting with ST-segment elevation myocardial infarction (STEMI) are at highest risk. Objectives: The goal of this study was to determine the clinical characteristics, management, and outcomes of STEMI after TAVR. Methods: This was a multicenter study including 118 patients presenting with STEMI at a median of 255 days (interquartile range: 9 to 680 days) after TAVR. Procedural features of STEMI after TAVR managed with primary percutaneous coronary intervention (PCI) were compared with all-comer STEMI: 439 non-TAVR patients who had primary PCI within the 2 weeks before and after each post-TAVR STEMI case in 5 participating centers from different countries. Results: Median door-to-balloon time was higher in TAVR patients (40 min [interquartile range: 25 to 57 min] vs. 30 min [interquartile range: 25 to 35 min]; p = 0.003). Procedural time, fluoroscopy time, dose-area product, and contrast volume were also higher in TAVR patients (p < 0.01 for all). PCI failure occurred more frequently in patients with previous TAVR (16.5% vs. 3.9%; p < 0.001), including 5 patients in whom the culprit lesion was not revascularized owing to coronary ostia cannulation failure. In-hospital and late (median of 7 months [interquartile range: 1 to 21 months]) mortality rates were 25.4% and 42.4%, respectively (20.6% and 38.2% in primary PCI patients), and estimated glomerular filtration rate <60 ml/min (hazard ratio [HR]: 3.02; 95% confidence interval [CI]: 1.42 to 6.43; p = 0.004), Killip class ≥2 (HR: 2.74; 95% CI: 1.37 to 5.49; p = 0.004), and PCI failure (HR: 3.23; 95% CI: 1.42 to 7.31; p = 0.005) determined an increased risk. Conclusions: STEMI after TAVR was associated with very high in-hospital and mid-term mortality. Longer door-to-balloon times and a higher PCI failure rate were observed in TAVR patients, partially due to coronary access issues specific to the TAVR population, and this was associated with poorer outcomes.
AB - Background: Among patients with acute coronary syndrome following transcatheter aortic valve replacement (TAVR), those presenting with ST-segment elevation myocardial infarction (STEMI) are at highest risk. Objectives: The goal of this study was to determine the clinical characteristics, management, and outcomes of STEMI after TAVR. Methods: This was a multicenter study including 118 patients presenting with STEMI at a median of 255 days (interquartile range: 9 to 680 days) after TAVR. Procedural features of STEMI after TAVR managed with primary percutaneous coronary intervention (PCI) were compared with all-comer STEMI: 439 non-TAVR patients who had primary PCI within the 2 weeks before and after each post-TAVR STEMI case in 5 participating centers from different countries. Results: Median door-to-balloon time was higher in TAVR patients (40 min [interquartile range: 25 to 57 min] vs. 30 min [interquartile range: 25 to 35 min]; p = 0.003). Procedural time, fluoroscopy time, dose-area product, and contrast volume were also higher in TAVR patients (p < 0.01 for all). PCI failure occurred more frequently in patients with previous TAVR (16.5% vs. 3.9%; p < 0.001), including 5 patients in whom the culprit lesion was not revascularized owing to coronary ostia cannulation failure. In-hospital and late (median of 7 months [interquartile range: 1 to 21 months]) mortality rates were 25.4% and 42.4%, respectively (20.6% and 38.2% in primary PCI patients), and estimated glomerular filtration rate <60 ml/min (hazard ratio [HR]: 3.02; 95% confidence interval [CI]: 1.42 to 6.43; p = 0.004), Killip class ≥2 (HR: 2.74; 95% CI: 1.37 to 5.49; p = 0.004), and PCI failure (HR: 3.23; 95% CI: 1.42 to 7.31; p = 0.005) determined an increased risk. Conclusions: STEMI after TAVR was associated with very high in-hospital and mid-term mortality. Longer door-to-balloon times and a higher PCI failure rate were observed in TAVR patients, partially due to coronary access issues specific to the TAVR population, and this was associated with poorer outcomes.
KW - ST-segment elevation myocardial infarction
KW - acute coronary syndrome
KW - mortality
KW - percutaneous coronary intervention
KW - transcatheter aortic valve replacement
UR - https://www.scopus.com/pages/publications/85104410822
U2 - 10.1016/j.jacc.2021.03.014
DO - 10.1016/j.jacc.2021.03.014
M3 - Article
SN - 0735-1097
VL - 77
SP - 2187
EP - 2199
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 17
ER -